{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:05:47Z","timestamp":1789243547698,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011841","name":"Xinxiang Medical University","doi-asserted-by":"publisher","award":["XYBSKYZZ202185"],"award-info":[{"award-number":["XYBSKYZZ202185"]}],"id":[{"id":"10.13039\/501100011841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110146","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:19:05Z","timestamp":1781911145000},"page":"110146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel NQO1\/STAT3\/HDAC triple-target agents for the treatment of triple negative breast cancer"],"prefix":"10.1016","volume":"180","author":[{"given":"Song","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingke","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110146_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116584","article-title":"Combining therapeutic vulnerabilities in triple negative breast cancer: stem-like traits explored within molecular classification","volume":"174","author":"Huang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.110146_bb0010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s11010-023-04772-6","article-title":"Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC)","volume":"479","author":"Mustafa","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2026.110146_bb0015","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3390\/diagnostics14171875","article-title":"Triple-negative breast cancer: molecular particularities still a challenge","volume":"14","author":"Varzaru","year":"2024","journal-title":"Diagnostics"},{"key":"10.1016\/j.bioorg.2026.110146_bb0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0025","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","article-title":"Triple negative breast cancer treatment options and limitations: future outlook","volume":"15","author":"Obidiro","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.110146_bb0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bioorg.2026.110146_bb0035","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110146_bb0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nrd3674","article-title":"Epigenetic protein families: a new frontier for drug discovery","volume":"11","author":"Arrowsmith","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110146_bb0045","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110146_bb0050","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-488114","article-title":"Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors","volume":"123","author":"Bots","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110146_bb0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110146_bb0060","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2015-03-632984","article-title":"Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies","volume":"126","author":"Matthews","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110146_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-017-0463-6","article-title":"Emerging therapies for acute myeloid leukemia","volume":"10","author":"Saygin","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0070","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1021\/acs.jmedchem.6b01538","article-title":"Alkoxyurea-based histone deacetylase inhibitors increase cisplatin potency in chemoresistant cancer cell lines","volume":"60","author":"Stenzel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110146_bb0075","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-025-07737-z","article-title":"Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials","volume":"212","author":"Mustafa","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bioorg.2026.110146_bb0080","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s40265-025-02248-z","article-title":"Ifupinostat: first approval","volume":"85","author":"Fung","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110146_bb0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/fon.12.173","article-title":"Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials","volume":"9","author":"Qiu","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0090","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/epi.14.73","article-title":"Epigenetic therapy for solid tumors: from bench science to clinical trials","volume":"7","author":"Juo","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.bioorg.2026.110146_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113825","article-title":"Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy","volume":"226","author":"Zhou","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110146_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112831","article-title":"Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment","volume":"208","author":"Peng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110146_bb0105","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0125","article-title":"Epigenetic therapeutics: reprogramming triple-negative breast cancer into responsive subtypes","volume":"32","author":"Ramadan","year":"2025","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bioorg.2026.110146_bb0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-013-2784-7","article-title":"Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin","volume":"143","author":"Shah","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bioorg.2026.110146_bb0115","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1158\/1535-7163.MCT-14-0778","article-title":"Histone deacetylase inhibitor entinostat inhibits tumor-initiating cells in triple-negative breast cancer cells","volume":"14","author":"Schech","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110146_bb0120","first-page":"1356","article-title":"Divergent JNK phosphorylation of HDAC3 in triple-negative breast cancer cells determines HDAC inhibitor binding and selectivity, cell","volume":"24","author":"Hanigan","year":"2017","journal-title":"Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0125","first-page":"116","article-title":"Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells","volume":"55","author":"Maiti","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0130","first-page":"299","article-title":"Histone deacetylases as new therapeutic targets in triple-negative breast cancer: progress and promises","volume":"14","author":"Garmpis","year":"2017","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.bioorg.2026.110146_bb0135","doi-asserted-by":"crossref","first-page":"114156","DOI":"10.18632\/oncotarget.23169","article-title":"HDAC inhibition potentiates immunotherapy in triple negative breast cancer","volume":"8","author":"Terranova-Barberio","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110146_bb0140","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1021\/acs.jmedchem.0c01180","article-title":"Small-molecule drug discovery in triple negative breast cancer: current situation and future directions","volume":"64","author":"Liao","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110146_bb0145","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccell.2016.08.001","article-title":"Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer","volume":"30","author":"Zeng","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110146_bb0150","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3390\/cancers11070955","article-title":"Metabolic regulation of redox balance in cancer","volume":"11","author":"Purohit","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110146_bb0155","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6175804","article-title":"ROS generation and antioxidant defense systems in normal and malignant cells","volume":"2019","author":"Snezhkina","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2026.110146_bb0160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1073\/pnas.0408732102","article-title":"Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors","volume":"102","author":"Ungerstedt","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.110146_bb0165","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3390\/cancers12040827","article-title":"xCT inhibition increases sensitivity to vorinostat in a ROS-dependent manner","volume":"12","author":"Miyamoto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110146_bb0170","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2009-11-256354","article-title":"Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound \u03b2-phenylethyl isothiocyanate","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110146_bb0175","article-title":"IR783-stabilized nanodrugs enhance anticancer immune response by synergizing oxidation therapy and epigenetic modulation","volume":"12","author":"Liu","year":"2025","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.bioorg.2026.110146_bb0180","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrd4088","article-title":"Therapeutic modulators of STAT signalling for human diseases","volume":"12","author":"Miklossy","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110146_bb0185","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110146_bb0190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110146_bb0195","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/ijc.29923","article-title":"Constitutive activation of STAT3 in breast cancer cells: a review","volume":"138","author":"Banerjee","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.110146_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110447","article-title":"Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: an updated review (from 2022 to 2024)","volume":"36","author":"Kang","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110146_bb0205","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/acs.jmedchem.1c00629","article-title":"Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110146_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114053","article-title":"A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction","volume":"178","author":"Park","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0215","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/biomedicines9040436","article-title":"Antitumor activity of pulvomycin via targeting activated-STAT3 signaling in docetaxel-resistant triple-negative breast cancer cells","volume":"9","author":"Byun","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2026.110146_bb0220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","article-title":"STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review","volume":"38","author":"Qin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110146_bb0225","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1021\/acs.jmedchem.8b00124","article-title":"NAD(P)H:quinone oxidoreductase 1 (NQO1) as a therapeutic and diagnostic target in cancer","volume":"61","author":"Zhang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110146_bb0230","doi-asserted-by":"crossref","DOI":"10.1186\/1756-9966-33-14","article-title":"Clinical implications of high NQO1 expression in breast cancers","volume":"33","author":"Yang","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110146_bb0235","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3892\/or.2014.3494","article-title":"NAD(P)H:quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer","volume":"32","author":"Cui","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2026.110146_bb0240","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/mc.20107","article-title":"Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer","volume":"43","author":"Lewis","year":"2005","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2026.110146_bb0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.yexmp.2013.12.008","article-title":"Significance of NQO1 overexpression for prognostic evaluation of gastric adenocarcinoma","volume":"96","author":"Lin","year":"2014","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0250","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/mol.65.5.1238","article-title":"NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger","volume":"65","author":"Siegel","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0255","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1021\/cb4005832","article-title":"Efficient NQO1 substrates are potent and selective anticancer agents","volume":"8","author":"Parkinson","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0260","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1021\/acs.accounts.5b00365","article-title":"Deoxynyboquinones as NQO1-activated cancer therapeutics","volume":"48","author":"Parkinson","year":"2015","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.110146_bb0265","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1074\/jbc.275.8.5416","article-title":"NAD(P)H:quinone oxidoreductase activity is the principal determinant of \u03b2-lapachone cytotoxicity","volume":"275","author":"Pink","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110146_bb0270","first-page":"353","article-title":"NQO1-mediated biotransformation determines the cytotoxicity of tanshinone IIA","volume":"10","author":"Liu","year":"2012","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110146_bb0275","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/1078-0432.CCR-19-0302","article-title":"Bioactivation of napabucasin triggers reactive oxygen species-mediated cancer cell death","volume":"25","author":"Froeling","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110146_bb0280","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1158\/0008-5472.CAN-24-0800","article-title":"Simultaneous targeting of NQO1 and SOD1 eradicates breast cancer stem cells via mitochondrial futile redox cycling","volume":"84","author":"Luo","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110146_bb0285","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1089\/ars.2013.5462","article-title":"Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers","volume":"21","author":"Cao","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bioorg.2026.110146_bb0290","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/np50023a014","article-title":"Plant anticancer agents. XII. Isolation and structure elucidation of new cytotoxic quinones from Tabebuia cassinoides","volume":"45","author":"Rao","year":"1982","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2026.110146_bb0295","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.3390\/molecules28155678","article-title":"The anticancer effect of napabucasin (BBI608), a natural naphthoquinone","volume":"28","author":"Shao","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2026.110146_bb0300","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1021\/acs.jnatprod.8b00247","article-title":"Napabucasin and related heterocycle-fused naphthoquinones as STAT3 inhibitors with antiproliferative activity against cancer cells","volume":"81","author":"L\u00f6cken","year":"2018","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bioorg.2026.110146_bb0305","first-page":"1442","article-title":"NQO1 is a determinant for cellular sensitivity to anti-tumor agent napabucasin","volume":"10","author":"Guo","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110146_bb0310","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00280-025-04770-z","article-title":"Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function","volume":"95","author":"Yuan","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110146_bb0315","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201903121","article-title":"The nanoassembly of an intrinsically cytotoxic near-infrared dye for multifunctionally synergistic theranostics","volume":"15","author":"Xiao","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.bioorg.2026.110146_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110447","article-title":"Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)","volume":"36","author":"Kang","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110146_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.109734","article-title":"Fisetin micelles precisely exhibit a radiosensitization effect by inhibiting PDGFR\u03b2\/STAT1\/STAT3\/Bcl-2 signaling pathway in tumor","volume":"36","author":"Zeng","year":"2025","journal-title":"Chin. Chem. Lett."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826006826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826006826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:25:16Z","timestamp":1789241116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826006826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":65,"alternative-id":["S0045206826006826"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110146","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel NQO1\/STAT3\/HDAC triple-target agents for the treatment of triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110146"}}